Vebicorvir clinical trials
Also written ABI-H0731.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How each study uses vebicorvir is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
8 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Assembly Biosciences (7) · Antios Therapeutics, Inc (1)
Often tested with
Tested in the same studies.
Pegylated Interferon Alfa (1) · Fosclevudine alafenamide (1)
Studies
Open first, then newest update. How each study uses vebicorvir is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With Chronic Hepatitis B Virus InfectionTerminatedPhase 2Assembly BiosciencesNCT04781647Written as ABI-H0731
- A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase InhibitorsTerminatedPhase 2Assembly BiosciencesNCT04454567Written as ABI-H0731
- A Study of Safety and Efficacy of ATI-2173 and Vebicorvir in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus InfectionTerminatedPhase 2Antios Therapeutics, IncNCT05238844Written as Vebicorvir 300mg
- A Study Evaluating ABI-H0731 as Adjunctive Therapy in Participants With Chronic Hepatitis B InfectionCompletedPhase 2Assembly BiosciencesNCT03576066Written as ABI-H0731
- A Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Participants With Chronic Hepatitis B Virus Infection (cHBV)CompletedPhase 2Assembly BiosciencesNCT03577171Written as ABI-H0731
- A Study to Evaluate the Mass Balance Absorption and AME of VBRCompletedPhase 1Assembly BiosciencesNCT04637139Written as Vebicorvir (VBR)
- A Study in Healthy Volunteers and Patients With Chronic Hepatitis BCompletedPhase 1Assembly BiosciencesNCT02908191Written as ABI-H0731
- Phase 1b/2a Study of ABI-H0731 in Patients With Chronic Hepatitis BCompletedPhase 1/2Assembly BiosciencesNCT03109730Written as ABI-H0731
Codes
What other systems call vebicorvir · ClinicalTrials.gg INT014288
- UNII (FDA) 16F6055SMGVEBICORVIROne source FDA
- NCI Thesaurus C175206VebicorvirOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 16F6055SMG | VEBICORVIR | One source FDA |
| NCI Thesaurus | C175206 | Vebicorvir | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.